Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food ... after Novo shared positive headline results from a late-stage study evaluating a higher dose of semaglutide in adults with ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

Patients testing a new weight-loss drug developed by the creators of Ozempic have revealed the extreme effects it had on their bodies. Danish pharma giant Novo Nordisk has been tight-lipped ...

Novo Nordisk shares rose Wednesday after fourth ... People taking Wegovy start off on the lowest dose – or the starter dose – then work their way up to stronger formulations so their bodies ...